OncoMatch/Clinical Trials/NCT04879329
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Is NCT04879329 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including disitamab vedotin and pembrolizumab for urothelial carcinoma.
Treatment: disitamab vedotin · pembrolizumab — This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) IHC 1+ (IHC 1+, 2+ or 3+)
HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
Required: HER2 (ERBB2) IHC 2+ (IHC 1+, 2+ or 3+)
HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
Required: HER2 (ERBB2) IHC 3+ (IHC 1+, 2+ or 3+)
HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner Gateway Medical Center · Gilbert, Arizona
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Kaiser Permanente Anaheim Kraemer Medical Offices · Anaheim, California
- Foothill Cardioology · Arcadia, California
- Kaiser Permanente Baldwin Park Medical Center · Baldwin Park, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify